Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Heart failure; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms HELP
  • Sponsors Tenax Therapeutics
  • Most Recent Events

    • 31 Oct 2019 According to a Tenax Therapeutics media release, Dr. Stuart Rich, Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute at Northwestern University is the principal investigator and architect for the HELP Study.
    • 31 Oct 2019 Interim results presented in a Tenax Therapeutics media release.
    • 31 Oct 2019 According to a Tenax Therapeutics media release, the company has activated all of its anticipate 15 sites which it believes will be sufficient to fully enroll the trial. 15 patients, up from eight at the end of August, are currently enrolled, out of the targeted 36 patients. Given the current pace of patient enrollment, we continue to expect full enrollment and top-line data in the first quarter of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top